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Abstract. Tenascin, together with thrombospondin
and SPARC, form a family of matrix proteins that,
when added to bovine aortic endothelial cells, caused
a dose-dependent reduction in the number of focal ad-
hesion-positive cells to -50% of albumin-treated con-
trols. For tenascin, a maximum response was obtained
with 20-60 jug/ml of protein. The reduction in focal
adhesions in tenascin-treated spread cells was observed
10 min after addition of the adhesion modulator,
reached the maximum by 45 min, and persisted for at
least 4 h in the continued presence of tenascin. This
effect was fully reversible, was independent of de novo
protein synthesis, and was neutralized by a polyclonal
antibody to tenascin. Monoclonal antibodies to spe-
cific domains of tenascin (mAbs 81C6 and 127) were
used to localize the active site to the alternatively
C
ELL substrate adhesion typically involves cellular rec-
ognition of an adhesive matrix protein (e.g., fibronec-
tin, laminin, vitronectin, or fibrinogen) by an inte-
grin. Integrins are a family of heterodimeric cell surface
receptors that recognize specific domains in adhesive ex-
tracellular matrix proteins (reviewed in reference 21). Sub-
sequent to attachment of cells to a substrate via integrins,
additional cell surface, cytoskeletal, and extracellular com-
ponents become engaged in the adhesion process, result-
ing in cell spreading and the formation of stable adhesion
plaques.
The dynamics of a living organism require that cell sub-
strate adhesion be regulated. During wound healing, em-
bryogenesis, and metastasis, processes in which cells pro-
liferate and migrate, cell-substrate adhesions disassemble
and reform (2, 5, 44). Previous studies have shown that ex-
posure of cells to tumor-promoting phorbol esters (17, 36)
or to certain growth factors (18, 19) can cause loss of focal
adhesions. More recently, studies demonstrate that certain
extracellular matrix molecules may participate in destabiliz-
ing or modulating cell-substrate contacts. Murphy-Ullrich
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spliced segment of tenascin . Furthermore, a recombi-
nant protein corresponding to the alternatively spliced
segment (fibronectin type III domains 6-12) was ex-
pressed in Escherichia coli and was active in causing
loss of focal adhesions, whereas a recombinant form
of a domain (domain 3) containing the RGD sequence
had no activity. Chondroitin-6-sulfate effectively neu-
tralized tenascin activity, whereas dermatan sulfate and
chondroitin-4-sulfate were less active and heparan sul-
fate and heparin were essentially inactive. Studies sug-
gest that galactosaminoglycans neutralize tenascin ac-
tivity through interactions with cell surface molecules.
Overall, our results demonstrate that tenascin, throm-
bospondin, and SPARC, acting as soluble ligands, are
able to provoke the loss of focal adhesions in well-
spread endothelial cells.
and Hook showed that thrombospondin (TSP)' caused a
loss of focal adhesion plaques from spread bovine aortic en-
dothelial (BAE) cells (30) . Sage et al . reported that SPARC
(osteonectin) causes rounding of BAE cells (26, 35).
Tenascin (also referred to as hexabrachion or cytotactin)
is a large oligomeric glycoprotein that has been implicated
as an adhesion modulator; however, its physiological role
remains unclear. Tenascin is localized primarily in develop-
ing tissues and in tumors (reviewed in 8, 12, 13) and, like
many matrix glycoproteins, it is composed of multiple do-
mains, which may have discrete functions (12, 16, 22, 23,
37). Alternative splicing ofmRNAresults in multiple forms
of the molecule with varying numbers of a 91 amino acid
motifresembling fibronectin type III (FN-III) domains (16,
23, 43) .
Tenascin is known to interact with other molecules of the
extracellular matrix. There is a strong binding oftenascin to
1. Abbreviations usedin thispaper: RAE, bovine aortic endothelial; C-4-S,
chondroitin-4-sulfate; C-6-S, chondroitin-6-sulfate ; FN-III, fibronectin
type III; IRM, interference reflection microscopy; TSP, thrombospondin.chondroitin sulfate proteoglycans from cell culture, cartilage
extracts, and embryonic brains (7, 20, 42). Tenascin also
binds to heparin and DNA (29), and a reversible binding of
tenascin to fibronectin in solution has been reported (26) .
Attachment of cells to tenascin-coated plastic has been
reported by several investigators (4, 10, 15); however, cells
attached to tenascin remain rounded and do not spread, un-
like cells attached to fibronectin substrates. Other workers
have emphasized the weakness or absence of cell attachment
to tenascin substrates (13, 14, 26-28). A weak and/or tran-
sient attachment would be expected whenever a cell ex-
presses receptors for the substrate molecule, even if these
receptors are not involved in promoting physiological cell
adhesion (12).
Several recent studies suggest that tenascin may act to in-
hibit adhesion to substrates like fibronectin. There are at
least two different anti-adhesion mechanisms. The adhesion
modulator may bind to the substrate in a manner which for
steric reasons interferes with the recognition of the adhesive
site by the appropriate integrin. This mechanism may be
operative when the large tenascin molecule is incorporated
into a mixed substrate or is allowed to bind to an adhesive
substrate (26) . A steric blocking may explain many of the
anti-adhesion activities reported for tenascin in vitro (10, 26,
28, 37, 39) ; it may also play a role in modulating adhesion
in vivo. A second anti-adhesion mechanism may involve in-
teraction of an adhesion modulator with specific receptors
that trigger anti-adhesive responses through second mes-
senger systems. Soluble tenascin inhibited the adhesion of
humanmammary carcinoma cellsto fibronectin-coatedplas-
tic and to collagen gels (11). Riou et al. (33) found that solu-
ble tenascin inhibited the spreading and migration of meso-
dermal cellson fibronectin substrates, although Lightner and
Erickson (26) reported no effect of soluble tenascin on initial
adhesion of fibroblasts to fibronectin. These effects may in-
volve a binding of tenascin to distinct cell receptors, result-
ing in a modulation of cell adhesion through a process in-
volving second messengers.
In this report, we characterize the ability of tenascin to
stimulate the loss of focal adhesions in BAE cells that have
been grown to confluency in the presence of serum and are
fully spread with well-developed focal adhesions. Further-
more, we map this activity to the alternatively spliced region
of the hexabrachion arm and show that tenascin activity is
neutralized by some galactosaminoglycans acting at the cell
surface. It should be noted that while previous studies have
focused on the ability of tenascin to modulate the initial at-
tachment and spreading of cells, in this study we are observ-
ing loss of focal adhesions in cellsthat have been fully spread
and attached for many hours.
Materials andMethods
Materials
The following items were purchased: DME (Cell-Gro; Mediatech, Inc.,
Herndon, VA); FBS (Hyclone Laboratories Inc., Logan, UT); trypsin-
EDTA (Gibco Laboratories, Grand Island, NY); BSA, cycloheximide, and
glutaraldehyde (Sigma Chemical Co., St. Louis, MO); NBD-phallicidin
(Molecular Probes, Inc., Eugene, OR); and chondroitinase ABC (Sei-
kagaku America Inc., Rockville, MD).
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Proteins and Glycosaminoglycans
TSP was purified from fresh human platelets purchased from the Birming-
ham American Red Cross (Birmingham, AL) using affinity chromatogra-
phy on a column of heparin-Sepharose CL-6B (Pharmacia Fine Chemicals,
Piscataway, NJ) and gel permeationchromatography on a column ofÁ0.5m
resin (Bio-Rad Laboratories, Richmond, CA) (31). Tenascin was purified
from culture supernatants of U-251MG human glioma cells by ammonium
sulfate precipitation, followed by gel permeation chromatography on a
column of Sephacryl S-500 HR and anion exchange chromatography on a
MonoQ column (1). Some preparations were further purified by a second
chromatography step on a Sephacryl S-500HR column (1). Protein concen-
tration wasdetermined from the absorbance at 278 run, using the extinction
coefficient 0.97 (40). Thepurifiedtenascin preparations fromthe U-251MG
cells consisted of at least 95% of the large form (320-kD subunit) of the
hexabrachion molecule. Tenascin was purified from U87 cells using the
same protocol as for U-251 cells; however, yields of protein from this cell
line were significantly lower than from U-251MG cells. Humanfibronectin
and vitronectin were generous gifts of Dr. Deane Mosher, Department of
Physiological Chemistry, University of Wisconsin (Madison, WI). Bovine
vitronectin and rat laminin were purchased from Telios Pharmaceuticals,
Inc. (San Diego, CA). Human fibrinogen from KABI-Vitrium AB (Stock-
holm, Sweden) depletedofcontaminating fibronectin was a gift of Dr. Lech
Switalski, Departmentof Microbiology, University of Alabama at Birming-
ham (Birmingham, AL). SPARC purified from the culture supernatants of
mouse PYS cells was agenerous gift of Dr. Helene Sage, Department of
Biological Structure, University ofWashington (Seattle, WA) (35). Thepu-
rity of the proteins was assessed by SDS-PAGE.
Isomers of chondroitin sulfate glycosaminoglycans were provided by Dr.
John Baker, Department of Biochemistry, University ofAlabama at Birming-
ham (Birmingham, AL). Chondroitin-6-sulfate (C-6-S) glycosaminogly-
cans were purified from basking shark cartilage and Chondroitin-4-sulfate
(C-4-S) glycosaminoglycans were purified from a rat chondrosarcoma after
alkaline borohydride treatment ofthe proteoglycan according to the method
of Carlson (6) . Heparan sulfate from bovine kidney and chondroitin sulfate
B (dermatan sulfate), C (C-6-S), D, and E, all "super special grade" when
available, were purchased from Seikagaku America Inc. Chondroitin sulfate
(shark cartilage, mixed isomers) and heparin (porcine intestinal mucosa)
were obtained from Sigma Chemical Co. Low molecular weight heparin
(3,000 mol wt) wasobtained from Boehringer Mannheim Biochemicals (In-
dianapolis, IN). Uronic acid contents were determinedaccording to the car-
bazole method of Bitter and Muir (3) .
Cells
BAEcells were provided by Dr. Robert Auerbach, Department of Zoology,
University of Wisconsin (Madison, WI). Cells were characterized in Dr.
Auerbach's laboratory as homogeneous populations of endothelial cells by
positive fluorescence for factor VIII antigen and uptake of acetylated low-
density lipoproteins, and by being positive for angiotensin-converting en-
zyme. Cells were routinely cultured in DMEsupplemented with 4.5 glliter
glucose, 2 mM glutamine, and 20% FBS. Cultures were passaged when
confluent by detaching the cells with trypsin-EDTA. Cells were used be-
tween passages 6 and 13.
Antibodies
Monoclonal anti-vinculinascites fluid (cloneVIN-11-5) was purchased from
Sigma Chemical Co. Rhodamine-labeled goat anti-mouse IgG was ob-
tained from Cappel Laboratories (Malvern, PA). Rabbit anti-human tenas-
cin antiserum was purchased from Telios Pharmaceuticals, Inc. The IgG
fraction was isolated by affinity chromatography on a column of Protein
A-Sepharose. The specificity of the antibody was analyzed by Western
blots. The isolated IgGwastested against rat laminin, human fibronectin,
human TSP, and SDSextracts of BAEcells and normal human skin fibro-
blasts fractionated by SDS-PAGE. The antibody recognized the purified
tenascin and bands ofthe same molecular weight as tenascin in conditioned
medium of normal skin fibroblasts. Theantibody did not react with any of
the other purified proteins or the cell extracts.
Thelocations of the epitopes for several hexabrachion mAbs have been
mapped by electron microscopyandWesternblotting (unpublished results),
and are shown schematically in Fig. 1. Electron microscopy showed that
mAb58 bound to the central nodule and mAb 2A6bound to the terminal
knob. mAbs 190, 127, and 81C6 bound to the thick segment of the hex-
abrachion arm, which comprises the FN-III domains, and have been more
1128Figure 1 . Mapping ofmAb epitopes . (A) A diagram of one arm of
the human hexabrachion showing the domain structure and likely
positions ofmAbs as determined by electron microscopy and West-
ern blotting . The NH Z-terminus (at the central nodule) is on the
left, and the COOH-terminus (the fibrinogen-like terminal knob)
is on the right . EGF-like domains are round, and FN-III domains
are rounded squares . The largest alternatively spliced domains are
shaded . (B) Western blot of native tenascin with different mAbs .
Electrophoresis on a 5% nonreducing gel was from left to right .
The arrows, from left to right, mark the position of the 320-, 230-,
and 220-kD splice variants . The upper panel shows tenascin pu-
rified fromU-251MG cell culture, and the lower panel shows tenas-
cin from the U87 glioma cell line, in which the two lower molecular
weight splice variants are more abundant . The CONT lane was
stained with a mAb not specific for tenascin . mAbs 190 and 58
stain all three splice variants, 81C6 stains the 320- and 230-, but
not the 220AD band, and 127 strains only the 320AD band .
precisely mapped by Western blotting . mAb 190 recognized a recombinant
form corresponding to FN-III domain 3 (the domain with the RGD se-
quence) . mAbs 127 and 81C6 reacted with the recombinant protein HxB6-
12, which is composed of the alternatively spliced segment (see below), and
their epitopes are thus localized in this domain . mAb 81C6 can be mapped
more precisely to FN-III domain 12 because it stains the 320- and 230-kD
bands ofnative tenascin, but not the 220-kD bands (Fig . 1), which is proba-
bly missing domain 12 (12) . Based on staining ofproteolytic fragments, we
tentatively map mAb 127 to one of the FN-III domains 7-9.
FocalAdhesion Assays
Focal adhesion assays were performed as described (30) . Briefly, BAE cells
were grown for 24-48 h on glass coverslips in DME with 20% FBS until
just confluent. Cells were treated for 1 h with 10 Ag/ml cycloheximide in
serum-containing medium to minimize interference from proteins synthe-
sized during the course of the experiments . Unless specifically indicated,
cycloheximide was present during all stages of the experiment before fixa-
tion . Cells were then rinsed with warmed DME to remove serum compo-
nents and incubated with tenascin or other agents diluted in DME for the
indicated time . Cells were fixed with 3 % warmed glutaraldehyde for 30
min, washed, and examined by interference reflection microscopy using a
Nikon Optiphot microscope. A minimum of 200 cells per condition were
routinely counted unless indicated otherwise. All experiments were per-
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formed at least twice, with most being performed three or four times . The
central observations that tenascin and the HxB6-12 fragment cause a loss
of focal adhesions were confirmed by a second person who performed the
assays with blinded samples . Cells were prepared for immunofluorescence
using methods and antibodies as previously described (30) .
CloningandExpression ofTenascin Segment HxB612
The bacterial expression system of Studier et al . (38), based on the T7 pro-
moter and inducible T7 polymerase, was used to express specific segments
ofthe tenascin molecule. TheDNAcorresponding to the entire alternatively
spliced segment (FN-III repeats 6-12) was amplified by polymerase chain
reaction, usingcDNA prepared from the U-251MG cells as template . The
forward and reverse primers corresponded to the amino acid sequences
EQAPE and SAIAT (beginning of domain 6 and end ofdomain 12 (16) . Re-
striction sites Ndel and BamHl were included in the primers to permit direc-
tional cloning ofthe amplified segment into the pET llb expression vector .
The resulting plasmid was used to transform the Escherichia coli strain
BL21(DE3) (38) . After the transformed E. call was induced with 0.4mM
IPTG for 3 h, a prominent 67-kD protein was detected in the lysate of the
cells and analyzed on SDS-PAGE (Fig. 2) . This protein was only present
in minute quantities before induction and was found to react with anti-
tenascin antibodies . This recombinant protein segment of tenascin, named
HxB6-12, was purified by precipitation with 25 % ammonium sulfate, fol-
lowed by chromatography on a MonoQ column . The Mono Q column gave
a cleanly separated peak that eluted at 0.31 M NaCl, followed by several
peaks that eluted at 0.37-0.41 M NaCl. All peaks showed predominantly
or exclusively the 67-kD band on 10% SDS-PAGE (Fig. 2) . The first peak
was identified as a monomeric protein by glycerol gradient sedimentation
and electron microscopy (see Fig. 2) ; this material was used in the focal
adhesion assays. The later peaks were oligomers comprising 3-10 subunits .
32 mg of monomer and 120 mg ofoligomer were obtained per liter ofbac-
terial culture . On Western blot analysis (not shown) the 67-kD HxB6-12
stained with our polyclonal antibody and with mAbs 127 and 81C6, but not
with mAb 190, consistent with our mapping of these antigenic sites (Fig .
1 A) . A 10-kD recombinant protein segment of tenascin corresponding to
FN-III domain 3, which contains the RGD sequence, was produced and
purified by a similar protocol (I . Aukhil, P. Joshi, Y Z . Yan, and H . P
Erickson, unpublished results) .
Results
Modulation ofFocalAdhesions Is aProperty ofSome,
butNotAllMatrix Molecules
TSP has previously been shown to stimulate the disappear-
ance of focal adhesions from spread BAE cells (30) . To de-
termine whether this effect is a general property of extracel-
lular matrix proteins, confluent BAE cells were incubated
with 10-301~g of fibronectin, fibrinogen, vitronectin, lami-
nin, TSP, tenascin, or SPARC. Subsequently, cells were ex-
amined for focal adhesions . The results of this experiment
showed that the matrix proteins can be divided into two
groups based on their effects on preformed focal adhesions
(Fig . 3) . The first group consisted of fibronectin, fibrinogen,
laminin, and vitronectin, all matrix molecules with known
adhesiveproperties . These proteins did not affect the number
of cells with focal adhesions or the distribution of adhesion
plaques over the cell body. The second group of matrix pro-
teins included TSP, tenascin, and SPARC, all of which
caused the loss of focal adhesions from -50% of the cells
with preformed adhesion plaques . Cells with three or fewer
adhesion plaques, which were generally located at the pe-
riphery of the cell, were scored as negative for focal adhe-
sions . Immunohistochemical staining of tenascin-treated cells
for vinculin and F-actin showed that the disappearance of
focal adhesions as observed by interference reflection mi-
croscopy (Fig . 4) corresponded to the absence of vinculin
plaques in the central region of the cells and a tendency for
1129Figure 2. Bacterially expressed segment HxB-12 . (A)SDS gel elec-
trophoresis of expression and purification of HxB6-12 . LaneMW
shows molecular weight standards, with the arrow indicatingBSA
(67 kD) ; lane 0 h is the bacterial pellet before induction ; lane 3 h
is the bacterial pellet after 3 h of induction ; lane pel is the pellet ;
and lane sup is the supernatant from the bacterial lysate . AmSO4
is the 25% ammonium sulfate pellet . Lanes MQ1 andMQ-2 are
the monomeric and oligomeric peaks from the Mono Q column .
(B) After sedimentation on glycerol gradients, rotary shadowed
electron microscope specimens of peak MQ-1 show rod-shaped
molecules measuring 20 run in length . (Bar is 100 nn) .
the F-actin to be distributed circumferentially (Fig. 5) . Loss
ofvinculin staining from plaque-like structures was often ob-
served in cells that had only a minimal alteration in F-actin
distribution or thickness of the stress fibers . This is consis-
tent with other observations which show that a loss ofvincu-
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Figure 3. Effect ofextracellular matrix proteins on focal adhesions
in BAE cells . Cells grown on coverslips in the presence of serum
were treated for 2 h at 37°C with the following proteins in a 500-11
volume : vitronectin (1014g), fibronectin (30 jig), laminin (30 hg),
fibrinogen (30 leg), tenascin (20 ug), TSP (30 ug), and SPARC
(1:20) . All cells were treated with 10 jg/ml cycloheximide for 1 h
before and during the incubation with proteins . Cells were fixed af-
ter the 2-h incubation and examined by IRM for the presence of fo-
cal adhesions. Results are expressed as percent of cells positive for
focal adhesions relative to BSA-treatedcontrols (100% corresponds
to 66% of total cells) .
lin can precede dissolution of the focal adhesion structure
(18) .
Approximately 30°10 of cells in the tenascin-treated culture
vs . 66% of cells in the BSA-treated cells retained focal adhe-
sions . These cells usually had 10-15 adhesion plaques dis-
tributed inboth the peripheral and central regions ofthe cells
(Fig . 4) . The cells that retained focal adhesions after treat-
ment with tenascin seem to constitute a general refractory
population, since the population of focal adhesion-positive
cells was not further reducedby simultaneous treatment with
tenascin and TSP The refractory cells contained similar
numbers and distributions of focal adhesions, as did positive
untreated (control) cells, and the distribution of adhesion
plaques in these two populations of cells was indistinguish-
able (Fig . 4) .
In these assays, tenascin slightly reduced the extent of cell
spreading, but it did not cause a general rounding of cells.
There was a 15% decrease in the number of cells that were
scored as spread when observed by phase contrast micros-
copy ; however, there was no significant difference in the
mean area of the spread cells after tenascin treatment (data
not shown) .
The effects oftenascinorTSPwere reversible. Ifcells were
washed free ofadhesion-modulating protein, focal adhesions
reassembled by til h, even in the continued presence of cy-
cloheximide (data not shown) .
Characterization ofTenascin-mediated Loss
ofFocal Adhesions in Spread Cells
The reduction in focal adhesion positive cells was dependent
on the amount of tenascin added to the cells (Fig. 6) . Half-
maximal tenascin activity (a decrease to 70% of control
cells) was obtained with 2-6 ug/mI (1-3 nM hexabrachion
or 6-18 nM monomer), and themaximum decrease in focal
adhesion positive cells to nearly 40% ofBSAtreated con-
trols was seen in cells treated with 60-200 pg/ml tenascin .
1130Figure 4. Interference reflection images of cells treated with tenascin . Cellsgrown in the presence of serum were washed and treated with
40 Ag/ml tenascin orBSA in serum-free medium for 1 h at 37°C, fixedandexamined byIRM. (a) BSA-treated cells have large focal adhesion
plaques distributed over the entire cell body (arrowheads) . (b) In contrast, tenascin-treated cells characteristically lack central focal adhe-
sions and have a somewhat homogeneous gray appearance. Bars = 10 Am .
Figure 5 . Vinculin and F-actin distribution in tenascin-treated cells is altered . Cells were treated with either 40 Ag/ml BSA (a, b) or 40
Ag/ml tenascin (c, d), fixedandpermeabilized, andthen stained with amAbto vinculin (a, c) or with NBD-phallicidin (b, d) . BSA-treated
controls have an extensive network ofactin-containing stress fibers (b)and vinculin-containing plaques located at the termini ofthese stress
fibers (a) . Tenascin-treated cells, in contrast, lack vinculin-containing plaques (c) . Staining for F-actin in tenascin-treated cells is found
primarily in a circumferential pattern (d) . Bars = 10 gym .
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Figure 6 . Tenascin-mediated loss of focal adhesions is dose depen-
dent . BAE cells were grown for 24 h on coverslips in DME with
20% FBS and then treated with 10 tug/ml cycloheximide for 90 min
before addition ofincreasing concentrations oftenascin in a 500-tul
volume . Cells were incubated with proteins for 1 h at 37°C, fixed,
and examined by IRM for the number of focal adhesion-positive
cells . A minimum of 100 cells were counted per coverslip . Results
are expressed as percent of spread cells positive for focal adhesions
relative to BSA-treated controls : 71% oftheBSAtreated cells were
positive for focal adhesions .
In experiments performed over several months with different
preparations of tenascin at 40 Fig/ml, the percent of focal
adhesion positive cells relative to the BSA-treated controls
was 55 f 10% (n = 34) .
The kinetics of the tenascin-mediated effect were exam-
ined . A nearly 10% reduction in focal adhesion positive cells
was observed as early as 10 min after the addition of tenas-
cin . The maximal reduction was observed by 45 min and per-
sisted over 4 h (Fig . 7) . In contrast, cells treated with TSP
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Figure 7 . Kinetics of response to tenascin and TSP . Confluent BAE
cells grown on coverslips in the presence of serum were pretreated
with 10 wg/ml cycloheximide for 1 h, washed, and treated with ei-
ther 60 ug/ml TSP (closedcircles), 40 lag/ml tenascin (closedtrian-
gles), or 60 tug/mlBSA (open circles) with cycloheximide in serum-
freeDME . Cells were incubated with the proteins for various times
(10, 20, 45, 60, 120, and 360 min) before fixation and examination
by IRM . Results are expressed as the percent of cells positive for
focal adhesions .
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did not show a reduction in focal adhesions until 20 min after
addition of TSP, and a maximal effect required 1-2 h of incu-
bation with TSP. Thus, BAE cells appear to be somewhat
more responsive to tenascin as compared with TSP.
Effect of Tenascin Is Neutralized
by Anti-Tenascin Antibodies
A rabbit polyclonal anti-tenascin antibody neutralized tenas-
cin's effect on focal adhesions . When the antibody was added
with tenascin (40 tug/ml) and incubated with the cells, 30
l~g/ml IgG neutralized 50% of tenascin activity and 100
/~g/ml antibody completely blocked tenascin activity (data
not shown) . Addition of antibody alone did not affect the
number of cells positive for focal adhesions . Nonimmune
rabbit IgG at 200 pg/ml did not inhibit tenascin activity and
anti-tenascin antibody had no effect on TSP-mediated loss of
focal adhesions (data not shown) .
In attempts to identify the domain in the hexabrachion
molecule responsible for its focal adhesion labilizing activ-
ity, mAbs reacting with different domains in the protein (Fig .
1 A) were tested for their ability to neutralize tenascin activ-
ity. Antibodies against the distal knob (mAb 2A6), the cen-
tral knob (mAb 58), and mAb 190, which recognizes the
third FN-III domain, had little or no effect on tenascin activ-
ity (Table I) . However, antibodies 127 and 81C6 effectively
neutralized the tenascin activity (Table I) . mAb 127 was
more effective at lower concentrations than 81C6. These two
neutralizing antibodies bind to different FN-III domains in
the alternatively spliced segment, suggesting that the anti-
adhesion activity is in this segment . Antibodies incubated
with cells in the absence of tenascin had no effect on focal
adhesions (data not shown) .
RecombinantFragmentHxB612Has
Tenascin-like Activity
To confirm the mapping ofthe focal adhesion modulating ac-
tivity to the alternatively spliced domain of tenascin, a
cDNA fragment corresponding to the entire alternatively
spliced segment of human tenascin comprising FN-III do-
mains 6-12 was expressed in E. coli . The recombinant pro-
Table I. Neutralization ofTenascin Activity by
Domain-Specific Monoclonal Antibodies
Tenascin
BSA
1132
42
66
Cells grown on coverslips were pretreated for 1 h with 10 Rg/ml cyclohexi-
mide, washed, and incubated for 1 h at 37°C with 40 /~g/ml tenascin or BSA
or with tenascin and antibodies . Cells were fixed and examined for focal adhe-
sions by interference reflection microscopy (IRM) . Antibodies alone did not
affect focal adhesions (data not shown) .
* Results in parentheses are expressed as percent neutralization of the reduc-
tion offocal adhesions in cells treated with antibody and tenascin as compared
with cells incubated with tenascin alone .
Percent of cells positive for focal adhesions
Antibody
Antibody
0 fig/ml 10 hg/ml
concentration
20 /'g/ml 60 wg/ml
Tenascin + mAb 58 - n .t . 48 (25)* n.t .
+ mAb 190 - n .t . 40 (0) n.t .
+ mAb 127 - 71 (122) 68 (108) 71 (122)
+ mAb 81C6 - 43 (3) 61 (78) 68 (108)
+ mAb 2A6 - n .t . 51 (36) n .t .w L
a
n
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0
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o tenascin
0 500 1000 1500 2000 2500 3000
Figure 8. Recombinant protein HxB6-12 has focaladhesion labiliz-
ing activity. Increasing concentrations of monomeric HxB6-12 or
native tenascin were tested in 1-h focal adhesion assays on BAE
cells grownon coverslips. Cells treated with 100 wg/ml BSA served
as positive controls. Results are expressed as percent of cells posi-
tive for focal adhesions.
tein, referred to as HxB6-12, was purified and shown to
cause a loss of focal adhesions from spread BAE cells in a
dose-dependent manner (Fig. 8). Although HxB6-12 reduced
the number of focal adhesion positive cellsto the same extent
as native tenascin, it was significantly less effective on a mo-
lar basis. Oligomeric preparations of HxB6-12 were also
tested and found to have activity at slightly lower concentra-
tions than the monomeric form ofHxB6-12 . Another recom-
binant protein, a 10-kD polypeptide equivalent to FN-III do-
main 3, which contains the RGD sequence, had no focal
adhesion labilizing activity.
Chondroitin SulfateGlycosaminoglycans Neutralize
Tenascin Activity
Since tenascin binds chondroitin sulfate proteoglycans (7,
20, 42) and TSP-induced loss of focal adhesions is neutral-
ized by heparin (30), we examined various glycosaminogly-
cans for their ability to neutralize tenascin activity. Two
preparations of C-6-S neutralized tenascin activity better
than either chondroitin sulfate B (dermatan sulfate) or C-4-S
(Table 11) . Over-sulfated isomers of chondroitin sulfate
(chondroitin sulfate D and E), heparin, or heparan sulfate at
200 ug/ml had no neutralizing activity. None of the
glycosaminoglycans alone affected the distribution or num-
ber of focal adhesions (data not shown) . Treatment of C-6-S
with chondroitinase ABC eliminated the ability of C-6-S to
neutralize tenascin activity (Table III), suggesting that C-6-S
activity was due to the glycosaminoglycan chains and not to
a possible contaminant. Chondroitinase treatment of tenas-
cin itself had no effect on tenascin activity.
C-6-S appears to neutralize tenascin activity through in-
teractions with the cell surface and does not have to be pres-
ent as a soluble molecule, since preincubation of cells with
C-6-S, followed by removal of unbound glycosaminoglycan
by washing before addition of tenascin, still resulted in neu-
tralization of tenascin activity (Table IV).
These data suggest that C-6-S bound to the cell surface
may either compete for binding to a tenascin receptor or, al-
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TableIL Tenascin Activity Is Neutralized
by C-6-SGlycosaminoglycan
Cells grown on coverslips were cycloheximide-treated before incubation for
1 h with tenascin and various glycosaminoglycans (used at 200 pg/ml). Cells
were then fixed and examined for the presence of focal adhesions by IRM.
Numbers in parentheses are data expressed as percent neutralization.
* This C-6-S is from Dr. John Baker, University of Alabama at Birmingham,
and was prepared from basking shark cartilage.
f This C-6-S (CS-C) was purchased from Seikagaku America Inc. C-4-S was
from Dr. John Baker and was purified from a rat chondrosarcoma. CS-B (der-
matan sulfate), CS-D, and CS-E (oversulfated isomers ofCS), and HS (bovine
kidney) were obtained from Seikagaku America Inc. Heparin (3,000 D) was
from Boehringer Mannheim Biochemicals.
ternately, sterically interfere with tenascin interactions with
this hypothetical receptor. In the latter case, longer glycos-
aminoglycan chains may be expected to block tenascin re-
ceptor accessibility more effectively than shorter chains. To
determine if the tenascin-neutralizing activity of the galac-
tosaminoglycans was related to the chain length of the poly-
mer, C-6-S and C-4-S preparations were subfractionated ac-
cording to size on a Sephacryl S-300 column . Fractions were
analyzed for uronic acid content by the carbazole method
and tested for neutralizing activity in focal adhesion assays
at -25 lAg (C-6-S) or 15 Ag (C-4-S) uronic acid. We ob-
served a relationship between the size of the glycosamino-
glycan chain and the ability to neutralize tenascin activity.
Table 111. C-6-SNeutralization ofTenascin Activity Is
Sensitive to Chondroitinase ABC Treatment
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Percent of cells positive for focal adhesions
500 Wg of C-6-S wasdigested for 18 h at 37*C with 0.1 U chondroitinase ABC.
200 pg/ml of digested or untreated C-6-S and/or 0.02 U enzyme were incu-
bated with cells in standard focal adhesion assays using 40 NLg/ml tenascin. In
some cases, enzyme was inactivated by boiling for 5 min before addition to
C-6-S. In control experiments, tenascin incubated for 18 h at 37°C with en-
zyme showed no decrease in activity as compared with control tenascin in-
cubated with buffer only . Results are expressed as the percentage of cells
positive for focal adhesions. Numbers in parentheses are data expressed rela-
tive to BSA-treated controls.
n, number of cells counted.
* Enzyme was inactivated by boiling for 5 min before addition to cells.
Experiment 1 Experiment 2
BSA (40,ug/ml) 67(100) BSA 79 (100)
Tenascin (40 kg/ml) 40 (0) Tenascin 55 (0)
Tenascin + C-6-S* 68(104) Tenascin + CS-D 57 (8)
+ C-6-S$ 62 (81) + CS-E 55 (0)
+ C-4-S 54 (52) + HS 54 (0)
+ CS-B 54 (52) + Heparin 57 (8)
Percent of
for focal
cells positive
adhesions
BSA 69 (100) n = 100
Tenascin 46 (67) n = 200
Tenascin + C-6-S 63 (91) n = 300
Tenascin + [C-6-S + enzyme]* 40 (58) n = 166
Tenascin + [C-6-S + inactive enzyme]* 61 (88) n = 302
Tenascin + enzyme 43 (62) n = 150
Tenascin + inactive enzyme 44 (64) n = 200
Enzyme 62 (90) n = 101
C-6-S + enzyme* 66 (96) n = 100Table IV. Neutralization ofTenascin Activity
by Preincubation ofCells with Chondroitin
Sulfate Glycosaminoglycan
Tenascin
C-6-S
￿
62 (102)
￿
59 (97)
DME
￿
61 (100)
￿
39(64)
Monolayers of BAE cells grown on coverslips were washed twice with DME
and then incubated for 1 h at 37°C with 10 pg/ml cycloheximide and 60 Wg/ml
of chondroitin sulfate-C (Seikagaku America Inc.) or DME. Coverslips were
then washed three times with warm DME and then incubated for 1 h with 40
ug/ml tenascin (+) or BSA (-), fixed, and examined for focal adhesions by
IRM. Results are expressed as percent ofcells positive for focal adhesions and
numbers inparentheses are percent of cells positive for focal adhesions relative
to the BSA-treated control.
Fractions of C-6-S of relatively longer chain length (glycos-
anlittoglycans eluted at Kev 0.147 and 0.235) completely neu-
tralized 20 lug tenascin activity; similarly, C-4-S chains eluted
at Kev 0.235 neutralized activity to 95 % of control . In con-
trast, glycosaminoglycan fractions of either C-6-S or C-4-S
that eluted at greater Key's (0.31-0.5), i.e., having a shorter
chain length, were decreasingly effective in neutralizing te-
nascin activity (Fig. 9).
Discussion
Previous observations, together with the data presented here,
suggest the existence of two families ofmatrix glycoproteins
that differ with respect to their effects on cell substrate adhe-
sion. The family ofadhesive matrix proteins, which include
fibronectin, vitronectin, fibrinogen, laminin, and some col-
lagens, promotes cell adhesion by facilitating cell attach-
ment, spreading, and formation of focal adhesions. The sec-
ond family of matrix proteins appears to negatively modulate
cell-substrate adhesion by apparently stimulating the disas-
sembly of focal adhesions in a subpopulation of spread cells.
Members ofthis adhesion-modulating family, which include
TSP, tenascin, and SPARC, are similar in that their expres-
sion is increased during neoplasia, embryogenesis, and tis-
sue remodeling and repair, processes in which cells undergo
mitosis and become motile (5). Cells change shape and lose
their focal adhesions during mitosis. Furthermore, motile
and transformed cells have fewerand smaller focal adhesions
than nontransformed, stationary cells (2, 5, 44) . The expres-
sion of adhesion modulators during tissue remodeling may
provide the type of "loose" adhesion required by a motile or
mitotic cell.
Like TSP, tenascin affects focal adhesions in only a sub-
population of cells in our BAE cultures. A combination of
two adhesion modulators, TSP and tenascin, did not increase
the percent of susceptible cells, suggesting that some cells
are in a refractilephase in which they are unable to respond
to adhesion modulators. In the population of susceptible
cells, the modulation of focal adhesions is achieved without
the need for de novo protein synthesis, since focal adhesion
loss occurs in the presence of cycloheximide. Moreover, the
effects are reversible: after tenascin or TSP is removed, fo-
cal adhesions are reassembled in the continued presence of
cycloheximide. We also observed that cellsadhering to fibro-
nectin or vitronectin substrates are equally sensitive to tenas-
cin or TSP (Murphy-Ullrich, J. E ., unpublished results) .
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Figure 9. The ability of glycosaminoglycans to neutralize tenascin
activity is related to the size of the chains. 50 mg C-6-S (Seikagaku
America Inc.) (top) and 10 mg C-4-S (gift of Dr. John Baker) (bot
tom) were fractionated on a Sephacryl S-300 column equilibrated
in PBS (v. = 33 ml, vt = 101 ml). Fractions were analyzed by the
carbazole method for uronic acid content and the absorbance was
read at 525 rum (circles). Various fractions were then analyzed for
their ability to neutralize the activity of 20 leg tenascin in focal
adhesion assays (hatched bars). C-6-S fractions were used at -25
hg uronic acid andC-4-S fractions at -15 pg uronic acid . Theper-
cent ofcells positive in BSAcontrols is indicated by the dashed lines
(63 % forthe C-6-S experiment and57% for the C-4-S experiment).
For both types of chondroitin sulfates, the larger size chains were
more effective neutralizers of tenascin activity than the smaller size
GAG chains.
A panel of mAbs was used to locate the domain in the
tenascin molecule responsible for its adhesion-modulating
activity. Two neutralizing antibodies bound to the alterna-
tively spliced segment, suggesting that this region contained
the active site. A recombinant form of the alternatively
spliced segment did, in fact, exhibit focal adhesion modulat-
ing activity, although it was less potent on a molar basis than
native tenascin. This difference couldreflect lack of glycosy-
lation of this normally heavily glycosylated region (16), in-
correct folding, or the monomeric nature ofthe recombinant
protein. Nevertheless, these data strongly suggest that a ma-
jor active site is located in the alternatively spliced segment.
Mapping the adhesion-modulating activity to this segment
also suggests that mechanisms regulating the splicing of
tenascin mRNA may determine the activity of the protein.
Recent evidence from Weller et al. (43), shows that, at least
for mouse mesenchymal tissues, the larger form of tenascin
predominates during embryogenesis. In other embryonic tis-
sues the appearance of different splice forms of tenascin is
more complex (32). Weakening of cell-substrate contacts
and thereby "priming" cells for migration may be one of thefunctions of the large form oftenascin in embryogenesis and
tissue remodeling.
In our studies, we found that sulfated galactosaminogly-
cans neutralized the focal adhesion labilizing activity of
tenascin. Several investigators reported that tenascin binds
to chondroitin sulfate proteoglycan from muscle cell culture,
cartilage, and chick brain (7, 20, 42), but this interaction may
primarily involve the proteoglycan core protein (20) . Tenas-
cin does not appear to bind to the chondroitin sulfate
glycosaminoglycan, since we failed to demonstrate a binding
of biotin-labeled chondroitin sulfate to tenascin adsorbed to
a microtiter well (Zhou, F., M. Hook, and J. E. Murphy-Ull-
rich, unpublished observations) . Since chondroitin sulfate
neutralized tenascin activity after unbound glycosaminogly-
cans had been removed from preincubated cells, the observed
neutralization probably involves binding ofthe glycosamino-
glycan to a cell surface component. This galactosaminogly-
can binding component couldbe a hypothetical tenascin re-
ceptor (41) or a membrane component located in the vicinity
of this receptor. As a result, the galactosaminoglycan could
compete for or sterically hinder tenascin interactions with a
receptor. The latter hypothesis is supported by data which
show that longer glycosaminoglycan chains are more effec-
tive inhibitors of tenascin than are shorter chains. It is note-
worthy that heparin-like polysaccharides, which neutralize
the focal adhesion modulating activity of TSP, did not affect
tenascin activity.
Focal adhesions involve a very close apposition of the
membrane to the substrate (10-15 run) . It is unlikely that a
molecule as large as a hexabrachion (ti100-150 nm) would
be able to intercalate under the cell and act directly at the
extracellular face of the focal adhesion. It appears more
likely that tenascin binds to a cell surface molecule distant
from the focal adhesion site, perhaps on the dorsal surface.
Interaction of tenascin with a cell surface molecule might
trigger a cytoplasmic signal that alters the cytoskeleton or
disrupts interactions of cytoplasmic components ofadhesion
plaques with transmembrane receptors. A signaling mecha-
nism has been proposed for the ability of tenascin to inhibit
T cell activation, an immunomodulatory activity perhaps
related to an inhibition of cell adhesion (34). It is possible
that this hypothetical signaling involves a phosphoryla-
tion/dephosphorylation mechanism, although the role of
phosphorylation of focal adhesion components in the main-
tenance of adhesion plaque integrity is presently unclear
(reviewed in reference 5). Phorbol esters, which activate
protein kinase C, cause a rapid loss of focal adhesions (36)
and alterations in F-actin (17) . Lamb et al. (24) demonstrated
that activation or injection of protein kinase A into fibro-
blasts caused complete loss of actin-containing stress fibers
and presumably, associated focal adhesions. On the other
hand, Woods et al. recently showed that induction of focal
adhesion formation by the heparin-binding fragment of fi-
bronectin is blocked in the presence of agents which inhibit
protein kinase C (45; Woods, A., M. R. Austria, and J. R.
Couchman. 1990. J. Cell Biol. 111:19a. [Abstr.]). Physio-
logically, kinases are regulated by binding of ligands to
specific receptors. We have shown that interaction of three
extracellular matrix molecules, TSP, tenascin, and SPARC,
with cells stimulates the loss of focal adhesions. Our future
work will focus on determining the signal transduction mech-
anisms though which these matrix molecules might alter fo-
cal adhesion integrity.
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